CYANVAC
Cyanvac develops vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. It is currently focused on developing robust, intranasal vaccines that are easy to administer, easy to transport, and easy to manufacture. Two of Cyanvac’s vaccine candidates are scheduled to enter clinical testing beginning in 2021, including an intrasal vaccine to serve as a booster for protecting against SARS-CoV-2 infection. The candidate was selected for the trial by an academic consortium that has run government-funded trials for other COVID-19 vaccines, and the clinical evaluation will be conducted at no cost to Cyanvac. Cyanvac also has vaccine candidates for the respiratory syncytial virus (RSV), norovirus, and Lyme Disease.
CYANVAC
Industry:
Biotechnology Health Care Manufacturing Medical Pharmaceutical
Founded:
2017-01-01
Address:
Athens, Georgia, United States
Country:
United States
Website Url:
http://www.cyanvacllc.com
Status:
Active
Contact:
(650) 518-9123
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Typekit
Current Employees Featured
Founder
Official Site Inspections
http://www.cyanvacllc.com Semrush global rank: 5.88 M Semrush visits lastest month: 1.41 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Cyanvac"
Cyanvac - Crunchbase Company Profile & Funding
Cyanvac develops vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector.See details»
Our Team - Cyanvac LLC
She has previously served as CFO and Controller for Cardiovascular Clinical Sciences, a full-service clinical research organization, and obtained a PhD in Biochemistry prior to embarking …See details»
CyanVac LLC Company Profile | Athens, GA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CyanVac LLC of Athens, GA. Get the latest business insights from Dun & Bradstreet.See details»
Cyanvac Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Cyanvac. Use the PitchBook Platform to explore the full profile.See details»
CyanVac | VentureRadar
Cyanvac LLC is developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. Our platform enables us to make robust, intranasal vaccines that are …See details»
Cyanvac LLC: Drug pipelines, Patents, Clinical trials - Synapse
Explore Cyanvac LLC with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 12 news, and 1 literature, Disease Domain:Infectious Diseases, Technology Platform:Vaccine, …See details»
Contact us - Cyanvac LLC
Please visit our affiliate, Blue Lake Biotechnology, for current opportunities.See details»
CyanVac CEO Speaks at White House Summit on the Future of …
Jul 27, 2022 CyanVac and Blue Lake Biotechnology are headquartered in Athens, Georgia, with a second site in Los Gatos, California. Learn more at https://www.cyanvacllc.com.See details»
CyanVac and Blue Lake Biotechnology Announce First Participant …
Sep 27, 2021 CyanVac and Blue Lake Biotechnology are headquartered in Athens, Georgia, with a second site in Los Altos, California. Learn more at https://www.cyanvacllc.com Forward …See details»
CyanVac and Blue Lake Biotechnology Announce FDA Clearance of …
Mar 28, 2022 CyanVac and Blue Lake Biotechnology are headquartered in Athens, Georgia, with a second site in Los Altos, California. Learn more at https://www.cyanvacllc.com Forward …See details»
CyanVac and Blue Lake Biotechnology Announce FDA Clearance of …
Mar 28, 2022 In addition, the companies have early-stage proof of concept vaccine programs targeting norovirus and Lyme disease. CyanVac and Blue Lake Biotechnology are …See details»
CyanVac Receives BARDA-Funded Project NextGen Award to …
Jun 13, 2024 CyanVac Receives BARDA-Funded Project NextGen Award to Evaluate its Intranasal COVID-19 Vaccine Candidate in a Phase 2b StudySee details»
Our Platform - Cyanvac LLC
Our Platform We are developing vaccines to protect the public from life-threatening diseases. Our proprietary vaccines are based on parainfluenza virus 5 (PIV5), also known as canine …See details»
CyanVac and Blue Lake Biotechnology Announce First ... - BioSpace
Sep 27, 2021 "The enrollment of the first participant in our first-in-human Phase 1 clinical trial marks another important milestone in our rapid growth as a vaccine company," said Dr. Biao …See details»
Blue Lake Biotechnology and CyanVac Announce Presentation on …
Oct 21, 2024 Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness theSee details»
Our Pipeline - Cyanvac LLC
Our Pipeline We are a technology-driven company with a proprietary PIV5 vaccine platform. Our pipeline features two clinical stage vaccines and additional vaccines in preclinical development.See details»
CyanVac Announces Data from Preclinical Studies of ... - BioSpace
Jun 10, 2022 ATHENS, Ga. and LOS GATOS, Calif., June 9, 2022 /PRNewswire/ -- CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a …See details»
CyanVac Announces Data from Preclinical Studies of Intranasal …
Jun 9, 2022 CVXGA1 is a clinical-stage COVID-19 vaccine candidate based on CyanVac's proprietary parainfluenza virus 5 (PIV5) vector that encodes the spike (S) protein of SARS …See details»
CyanVac Announces Data from Preclinical Studies of Intranasal …
Jun 9, 2022 Athens, GA and Los Gatos, CA , June 9, 2022. CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary …See details»